News
Stocktwits on MSN1d
AstraZeneca Gets Approval For Oncology Drug To Treat Mantle Cell Lymphoma In EU: But Retail Sentiment DipsShares of AstraZeneca (AZN) rose 1% on Tuesday morning after it announced that its Calquence (acalabrutinib) in combination ...
Medpage Today on MSN15h
'Armored' CAR T Cells Highly Active in Lymphoma After Prior CAR-T FailureA next-generation, anti-CD19 enhanced (or "armored") CAR T-cell product showed promising efficacy and safety in a phase I ...
GlobalData on MSN1d
EC approves AstraZeneca’s Calquence combo to treat MCLThe European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) ...
When Anthony Cannella was first diagnosed with mantle cell lymphoma, his youngest child was in kindergarten. He was told that ...
AstraZeneca (LSE:AZN) recently experienced positive developments, including the European approval of Calquence for mantle ...
DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working ...
AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...
Galapagos reported promising results from ATALANTA-1 study show 100% ORR/CR for relapsed Mantle Cell Lymphoma. Click for GLPG ...
Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...
AstraZeneca’s Calquence plus chemoimmunotherapy approved in EU to treat adult patients with previously untreated mantle cell lymphoma: Cambridge, UK Wednesday, May 7, 2025, 09:0 ...
A pan-tropomyosin receptor kinase (TRK) inhibitor, zurletrectinib (ICP-723) is said to have demonstrated better safety and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback